3VG.F THERANEXUS EO -25
- Market cap
- EUR 48.2M
- P/E
- -
- P/B
- 15.77x
- ROE
- -103.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 3VG.F undervalued?
Graham numberThe Graham number of THERANEXUS EO -25 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
THERANEXUS EO -25 fundamental analysis
No fundamental analysis for THERANEXUS EO -25 yet.
THERANEXUS EO -25 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About THERANEXUS EO -25
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pha…
Full company profileTHERANEXUS EO -25 financial statements
THERANEXUS EO -25 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.55M | -3.92M | -5.04M | -2.67M | -2.34M |
| Operating Income | -9.51M | -6.26M | -7.64M | -2.63M | -4.05M |
| EBITDA | - | -6.00M | -7.29M | -2.46M | -3.79M |
| Net Income | -8.15M | -6.57M | -6.83M | -1.77M | -3.00M |
| EPS | -1.63 | -1.24 | -0.87 | -0.21 | -0.22 |
| Balance Sheet | |||||
| Total Assets | 16.9M | 12.1M | 7.24M | 3.74M | 10.5M |
| Total Liabilities | 6.71M | 6.33M | 5.02M | 5.40M | 7.64M |
| Shareholders' Equity | 10.2M | 5.73M | 2.22M | -1.66M | 2.90M |
| Cash & Short-term Investments | 5.52M | 2.10M | 1.20M | 714K | 741K |
| Cash Flow | |||||
| Operating Cash Flow | -6.14M | -5.37M | -6.40M | -3.37M | -822K |
| Capital Expenditure | 151K | 73.6K | 43.6K | 32.7K | 257K |
| Free Cash Flow | -6.30M | -5.45M | -6.45M | -3.40M | -1.08M |
| Ratios | |||||
| ROE | -80.0% | -114.7% | -307.4% | - | -103.5% |
| ROA | -48.3% | -54.5% | -94.3% | -47.2% | -28.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
THERANEXUS EO -25 dividends
THERANEXUS EO -25 has not paid dividends in the last 6 fiscal years.
Who owns THERANEXUS EO -25
- Insiders 12.84%
- Institutions 19.74%
- Public & others 67.42%
- Shares outstanding 14.5M
- Free float 11.6M
THERANEXUS EO -25 company profile
- Company name
- THERANEXUS EO -25
- Ticker
- 3VG.F
- ISIN
- FR0013286259
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- December
- Address
- 60, Avenue Rockefeller, Lyon, France, 69008
- Phone
- 33 1 88 89 70 31
- Website
- theranexus.com
About THERANEXUS EO -25
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.
THERANEXUS EO -25 management
6- Mr. Mathieu CharvériatCo-Founder, Scientific Director, CEO & Chairman
- Mr. Franck MouthonCo-Founder & Director
- Mr. Julien VeysDeputy CEO, COO & Director
- Ms. Christine PlacetAdministrative & Financial Director · born 1963
- Ms. Francoise Vincent-LarrodeDirector of Human Resources
- Ms. Marie SebilleChief Medical Officer